Penumbra Inc.
Penumbra, Inc. Declassifies Board and Amends Voting Requirements
Summary
Penumbra, Inc. has implemented changes to its corporate governance structure, including the declassification of its Board of Directors and amendments to its voting requirements. These changes, approved by stockholders at the Annual Meeting on May 28, 2025, phase out the staggered board elections over three years and replace supermajority voting requirements with a simple majority standard for certain actions. The changes become effective immediately, with full declassification by the 2028 Annual Meeting.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement